Brightsurf Science News & Current Events

December 06, 2014
Advances in lymphoma and multiple myeloma treatment seek to improve outcomes for patients
New treatment combinations and targeted therapies for lymphoma and multiple myeloma are improving outcomes for vulnerable patient populations with hard-to-treat disease, according to studies presented today at the 56th American Society of Hematology Annual Meeting and Exposition.

Immunotherapy achieves breakthrough result in patients with Hodgkin lymphoma
Eighty-seven percent of Hodgkin lymphoma patients who participated in an early-phase immunotherapy clinical trial experienced cancer remission.

Unprecedented benefit seen in test of three-drug treatment for multiple myeloma
In the treatment of multiple myeloma, the addition of carfilzomib to a currently accepted two-drug combination produced significantly better results than using the two drugs alone, according to a worldwide research team led by investigators from Mayo Clinic.

Novel strategies direct immune system to attack recurrent, hard-to-treat blood cancers
Novel treatments that harness the body's own immune cells to attack cancer cells demonstrate safe and durable responses in patients with relapsed and treatment-resistant blood cancers, according to data presented today at the 56th American Society of Hematology Annual Meeting and Exposition.

Benefits persist in T cell therapy for children with relapsed leukemia
An innovative cell therapy against a highly aggressive form of acute lymphoblastic leukemia continues to show highly promising results in children treated in a pilot study.

Positive study data could improve standard of care for Hodgkin lymphoma patients
In a late-stage clinical trial, Hodgkin lymphoma patients who received brentuximab vedotin post-transplant lived longer without disease progression than patients who received only supportive care.

Circulating RNA may provide prognostic tool for multiple myeloma
The 'molecular mail' sent by multiple myeloma cells provides clues to how well patients with the disease are likely to respond to treatment, according to a study being presented at the annual meeting of the American Society of Hematology by researchers at Dana-Farber Cancer Institute.

Studies show immunotherapy drugs improve outcomes in Hodgkin lymphoma patients
In recent years, a number of scientific breakthroughs have led to the development of drugs that unleash the power of the immune system to recognize and attack cancer. is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to